Literature DB >> 9023272

The phosphodiesterase type 4 (PDE4) inhibitor CP-80,633 elevates plasma cyclic AMP levels and decreases tumor necrosis factor-alpha (TNFalpha) production in mice: effect of adrenalectomy.

J B Cheng1, J W Watson, C J Pazoles, J D Eskra, R J Griffiths, V L Cohan, C R Turner, H J Showell, E R Pettipher.   

Abstract

Rolipram was previously reported to elevate plasma cyclic adenosine 3',5'-monophosphate (cAMP) and inhibit serum tumor necrosis factor-alpha (TNF-alpha) production in mice. CP-80,633, a new cyclic nucleotide phosphodiesterase (PDE4) inhibitor, has been shown to augment intracellular cAMP levels and to inhibit TNFalpha release from human monocytes in vitro. This study was undertaken to determine the effect of p.o. CP-80,633 on plasma cAMP levels and lipopolysaccharide-induced TNFalpha production in mice with and without adrenal glands. CP-80,633 dose-dependently (3-32 mg/kg p.o.) elevated plasma cAMP levels and decreased systemic TNFalpha production in response to i.p. injection of lipopolysaccharide. Elevated plasma cAMP levels can be detected for up to 4 hr. CP-80,633 (10 mg/kg p.o.) caused a 6-fold increase in the plasma cAMP level, a 2-fold increase in the plasma epinephrine level and a greater than 95% reduction in TNFalpha production. Unlike CP-80,633, neither vinpocetine, dipyridamole, SKB-94,120 nor zaprinast, at 100 mg/kg p.o., modified the cAMP response, which suggests that this response is mediated by inhibition of PDE4. Adrenalectomy reduced the cAMP response and completely blocked the epinephrine response; however, the levels of plasma cAMP in the CP-80,633-treated mice (10 mg/kg p.o.) remained elevated (vehicle: 47.3 +/- 6.8 vs. CP-80,633: 98.4 +/- 10.3 pmol/ml, n = 7, P < .05). This effect is mimicked by treatment of control mice with propranolol, which demonstrates that beta adrenoreceptors contribute to the cAMP response. Removal of adrenal glands significantly increased the LPS-induced elevation of serum TNFalpha. The ability of CP-80,633 to block the TNFalpha response was only slightly affected by adrenalectomy (ED50 = 1.2 mg/kg in controls vs. 3.9 mg/kg in adrenalectomized mice). Taken together, these results show that CP-80,633, when given p.o. to mice, is capable of elevating plasma cAMP and inhibiting TNFalpha production and that adrenal catecholamines contribute significantly to the effect of CP-80,633 on the cAMP response but only slightly to its effect on the systemic TNFalpha response.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9023272

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

1.  Inhibitory effects of cyclic AMP elevating agents on lipopolysaccharide (LPS)-induced microvascular permeability change in mouse skin.

Authors:  K Irie; E Fujii; H Ishida; K Wada; T Suganuma; T Nishikori; T Yoshioka; T Muraki
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

2.  Inhibition of pulmonary eosinophilia and airway hyperresponsiveness in allergic mice by rolipram: involvement of endogenously released corticosterone and catecholamines.

Authors:  T T Kung; Y Crawley; B Luo; S Young; W Kreutner; R W Chapman
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

3.  Rolipram inhibits leukocyte-endothelial cell interactions in vivo through P- and E-selectin downregulation.

Authors:  María-Jesús Sanz; Angeles Alvarez; Laura Piqueras; Miguel Cerdá; Andrew C Issekutz; Roy R Lobb; Julio Cortijo; Esteban J Morcillo
Journal:  Br J Pharmacol       Date:  2002-04       Impact factor: 8.739

4.  Pharmacological blockade of CCR1 ameliorates murine arthritis and alters cytokine networks in vivo.

Authors:  M Amat; C F Benjamim; L M Williams; N Prats; E Terricabras; J Beleta; S L Kunkel; N Godessart
Journal:  Br J Pharmacol       Date:  2006-10-03       Impact factor: 8.739

5.  PK/PD studies on non-selective PDE inhibitors in rats using cAMP as a marker of pharmacological response.

Authors:  Artur Świerczek; Elżbieta Wyska; Sebastian Baś; Marta Woyciechowska; Jacek Mlynarski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-07-20       Impact factor: 3.000

6.  The absence of mrp4 has no effect on the recruitment of neutrophils and eosinophils into the lung after LPS, cigarette smoke or allergen challenge.

Authors:  Jürgen Schymeinsky; Hannah Mayer; Christopher Tomsic; Cornelia Tilp; John D Schuetz; Yunhai Cui; Lutz Wollin; Florian Gantner; Klaus J Erb
Journal:  PLoS One       Date:  2013-04-22       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.